<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37635943</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-1402</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>F1000Research</Title><ISOAbbreviation>F1000Res</ISOAbbreviation></Journal><ArticleTitle>The identification of high-performing antibodies for Charged multivesicular body protein 2b for use in Western Blot, immunoprecipitation and immunofluorescence.</ArticleTitle><Pagination><StartPage>884</StartPage><MedlinePgn>884</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">884</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.139755.1</ELocationID><Abstract><AbstractText>Charged multivesicular body protein 2B is a subunit of the endosomal sorting complex required for transport III (ESRCT-III), a complex implicated in the lysosomal degradation pathway and formation of multivesicular bodies. Mutations to the <i>CHMP2B</i> gene can result in abnormal protein aggregates in neurons and is therefore predicted to be associated in neurodegenerative diseases, including across the ALS-FTD spectrum.&#xa0;Through our standardized experimental protocol which compares read-outs in knockout cell lines and isogenic parental controls, this study aims to enhance the reproducibility of research on this target by characterizing eight commercial antibodies against charged multivesicular body protein 2b using Western Blot, immunoprecipitation, and immunofluorescence. We identified many high-performing antibodies and encourage readers to use this report as a guide to select the most appropriate antibody for their specific needs.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Alshafie W et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alshafie</LastName><ForeName>Walaa</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Qu&#xe9;bec, H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fotouhi</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Qu&#xe9;bec, H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayoubi</LastName><ForeName>Riham</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Qu&#xe9;bec, H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shlaifer</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The Neuro's Early Drug Discovery Unit (EDDU), Structural Genomics Consortium, McGill University, Montreal, Qu&#xe9;bec, H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Southern</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4125-3608</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Qu&#xe9;bec, H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McPherson</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Qu&#xe9;bec, H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laflamme</LastName><ForeName>Carl</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5906-025X</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Qu&#xe9;bec, H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NeuroSGC/YCharOS/EDDU collaborative group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FDN154305</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>F1000Res</MedlineTA><NlmUniqueID>101594320</NlmUniqueID><ISSNLinking>2046-1402</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057146" MajorTopicYN="N">Multivesicular Bodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CHMP2B</Keyword><Keyword MajorTopicYN="N">Charged multivesicular body protein 2b</Keyword><Keyword MajorTopicYN="N">Uniprot ID Q9UQN3</Keyword><Keyword MajorTopicYN="N">Western Blot</Keyword><Keyword MajorTopicYN="N">antibody characterization</Keyword><Keyword MajorTopicYN="N">antibody validation</Keyword><Keyword MajorTopicYN="N">immunofluorescence</Keyword><Keyword MajorTopicYN="N">immunoprecipitation</Keyword></KeywordList><CoiStatement>Competing interests: For this project, the laboratory of Peter McPherson developed partnerships with high-quality antibody manufacturers and knockout cell line providers. The partners provide antibodies and knockout cell lines to the McPherson laboratory at no cost. These partners include: - Abcam-Aviva Systems Biology -Bio Techne -Cell Signalling Technology -Developmental Studies Hybridoma Bank -GeneTex &#x2013; Horizon Discovery &#x2013; Proteintech &#x2013; Synaptic Systems &#x2013;Thermo Fisher Scientific.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>4</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37635943</ArticleId><ArticleId IdType="pmc">PMC10448144</ArticleId><ArticleId IdType="doi">10.12688/f1000research.139755.1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ugbode C, West RJH: Lessons learned from CHMP2B, implications for frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol. Dis. 2021;147:105144. 10.1016/j.nbd.2020.105144</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105144</ArticleId><ArticleId IdType="pubmed">33144171</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Bao H, Wang Z, et al. : Biogenesis and Function of Multivesicular Bodies in Plant Immunity. Front. Plant Sci. 2018;9:979. 10.3389/fpls.2018.00979</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpls.2018.00979</ArticleId><ArticleId IdType="pmc">PMC6047128</ArticleId><ArticleId IdType="pubmed">30038635</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper RC, Katzmann DJ: Biogenesis and function of multivesicular bodies. Annu. Rev. Cell Dev. Biol. 2007;23:519&#x2013;547. 10.1146/annurev.cellbio.23.090506.123319</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.23.090506.123319</ArticleId><ArticleId IdType="pmc">PMC2911632</ArticleId><ArticleId IdType="pubmed">17506697</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson N, Ince PG, Smith MO, et al. : ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology. 2006;67(6):1074&#x2013;1077. 10.1212/01.wnl.0000231510.89311.8b</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000231510.89311.8b</ArticleId><ArticleId IdType="pubmed">16807408</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G, Parkinson NJ, Brown JM, et al. : Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 2005;37(8):806&#x2013;808. 10.1038/ng1609</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1609</ArticleId><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Laflamme C, McKeever PM, Kumar R, et al. : Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72. elife. 2019;8:8. 10.7554/eLife.48363</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.48363</ArticleId><ArticleId IdType="pmc">PMC6794092</ArticleId><ArticleId IdType="pubmed">31612854</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshafie W, Fotouhi M, Shlaifer I, et al. : Identification of highly specific antibodies for Serine/threonine-protein kinase TBK1 for use in immunoblot, immunoprecipitation and immunofluorescence. F1000Res. 2022;11:977. 10.12688/f1000research.124632.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.124632.1</ArticleId><ArticleId IdType="pmc">PMC9647147</ArticleId><ArticleId IdType="pubmed">36415206</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Herrmann CJ, Simonovic M, et al. : Version 4.0 of PaxDb: Protein abundance data, integrated across model organisms, tissues, and cell-lines. Proteomics. 2015;15(18):3163&#x2013;3168. 10.1002/pmic.201400441</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201400441</ArticleId><ArticleId IdType="pmc">PMC6680238</ArticleId><ArticleId IdType="pubmed">25656970</ArticleId></ArticleIdList></Reference><Reference><Citation>DepMap, Broad: DepMap 19Q3 Public ed. 2019.</Citation></Reference><Reference><Citation>Alshafie W, Ayoubi R, Fotouhi M, et al. : The identification of high-performing antibodies for Moesin for use in Western Blot, immunoprecipitation, and immunofluorescence [version 1; peer review: awaiting peer review]. F1000Res. 2023;12:172. 10.12688/f1000research.130126.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.130126.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubi R, Fotouhi M, Southern K, et al. : The identification of high-performing antibodies for transmembrane protein 106B (TMEM106B) for use in Western blot, immunoprecipitation, and immunofluorescence [version 1; peer review: awaiting peer review]. F1000Res. 2023;12:308. 10.12688/f1000research.131333.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.131333.1</ArticleId><ArticleId IdType="pmc">PMC10403746</ArticleId><ArticleId IdType="pubmed">37545650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubi R, Alshafie W, Shlaifer I, et al. : The identification of high-performing antibodies for Sequestosome-1 for use in Western blot, immunoprecipitation and immunofluorescence [version 1; peer review: awaiting peer review]. F1000Res. 2023;12:324. 10.12688/f1000research.132628.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.132628.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubi R, McDowell I, Fotouhi M, et al. : The identification of high-performing antibodies for Profilin-1 for use in Western blot, immunoprecipitation and immunofluorescence [version 1; peer review: awaiting peer review]. F1000Res. 2023;12:348. 10.12688/f1000research.132249.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.132249.1</ArticleId><ArticleId IdType="pmc">PMC10415725</ArticleId><ArticleId IdType="pubmed">37576538</ArticleId></ArticleIdList></Reference><Reference><Citation>McDowell I, Ayoubi R, Fotouhi M, et al. : The identification of high-preforming antibodies for Ubiquilin-2 for use in Western Blot, immunoprecipitation, and immunofluorescence [version 1; peer review: awaiting peer review]. F1000Res. 2023;12:355. 10.12688/f1000research.131851.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.131851.1</ArticleId><ArticleId IdType="pmc">PMC10285353</ArticleId><ArticleId IdType="pubmed">37359784</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshafie W, Fotouhi M, Ayoubi R, et al. : The identification of high-performing antibodies for RNA-binding protein FUS for use in Western Blot, immunoprecipitation, and immunofluorescence [version 1; peer review: 1 approved with reservations]. F1000Res. 2023;12:376. 10.12688/f1000research.133220.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.133220.2</ArticleId><ArticleId IdType="pmc">PMC10293799</ArticleId><ArticleId IdType="pubmed">37384305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubi R, Alshafie W, Southern K, et al. : The identification of high-performing antibodies for Coiled-coil-helix-coiled-coil-helix domain containing protein 10 (CHCHD10) for use in Western Blot, immunoprecipitation and immunofluorescence [version 1; peer review: awaiting peer review]. F1000Res. 2023;12:403. 10.12688/f1000research.133479.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.133479.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Worrall D, Ayoubi R, Fotouhi M, et al. : The identification of high-performing antibodies for TDP-43 for use in Western Blot, immunoprecipitation and immunofluorescence [version 1; peer review: awaiting peer review]. F1000Res. 2023;12:277. 10.12688/f1000research.131852.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.131852.2</ArticleId><ArticleId IdType="pmc">PMC10285334</ArticleId><ArticleId IdType="pubmed">37359785</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubi R, Fotouhi M, Southern K, et al. : The identification of high-performing antibodies for Vacuolar protein sorting-associated protein 35 (hVPS35) for use in Western Blot, immunoprecipitation and immunofluorescence [version 1; peer review: awaiting peer review]. F1000Res. 2023;12:452. 10.12688/f1000research.133696.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.133696.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubi R, Alshafie W, You Z, et al. : The identification of high-performing antibodies for Superoxide dismutase [Cu-Zn] 1 (SOD1) for use in Western blot, immunoprecipitation, and immunofluorescence [version 1; peer review: awaiting peer review]. F1000Res. 2023;12:391. 10.12688/f1000research.132952.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.132952.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshafie W, McPherson P, Laflamme C: Antibody screening by Immunofluorescence. Zenodo. 2021. 10.5281/zenodo.5717498</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.5717498</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotouhi M, Alshafie W, Shlaifer I, et al. : Antibody Characterization Report for Charged multivesicular body protein 2b.[Dataset]. Zenodo. 2022. 10.5281/zenodo.6370501</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.6370501</ArticleId></ArticleIdList></Reference><Reference><Citation>Southern K: Dataset for the Charged multivesicular body protein 2b antibody screening study[Dataset]. Zenodo. 2023. 10.5281/zenodo.8139356</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.8139356</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandrowski A, Pairish M, Eckmann P, et al. : The Antibody Registry: ten years of registering antibodies. Nucleic Acids Res. 2022;51:D358&#x2013;D367. 10.1093/nar/gkac927</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac927</ArticleId><ArticleId IdType="pmc">PMC9825422</ArticleId><ArticleId IdType="pubmed">36370112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bairoch A: The Cellosaurus, a Cell-Line Knowledge Resource. J. Biomol. Tech. 2018;29(2):25&#x2013;38. 10.7171/jbt.18-2902-002</Citation><ArticleIdList><ArticleId IdType="doi">10.7171/jbt.18-2902-002</ArticleId><ArticleId IdType="pmc">PMC5945021</ArticleId><ArticleId IdType="pubmed">29805321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubi R, McPherson PS, Laflamme C: Antibody Screening by Immunoblot. Zenodo. 2021. 10.5281/zenodo.5717510</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.5717510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubi R, Fotouhi M, McPherson P, et al. : Antibody screening by Immunoprecitation. Zenodo. 2021. 10.5281/zenodo.5717516</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.5717516</ArticleId></ArticleIdList></Reference><Reference><Citation>: Intraneuronal sortilin aggregation relative to granulovacuolar degeneration, tau pathogenesis and sorfra plaque formation in human hippocampal formation. Front Aging Neurosci .2022;14: 10.3389/fnagi.2022.926904 926904 10.3389/fnagi.2022.926904</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.926904</ArticleId><ArticleId IdType="pmc">PMC9376392</ArticleId><ArticleId IdType="pubmed">35978952</ArticleId></ArticleIdList></Reference><Reference><Citation>: Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue byTMEM106B knockdown. Brain .2018;141(12) : 10.1093/brain/awy284 3428-3442 10.1093/brain/awy284</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy284</ArticleId><ArticleId IdType="pmc">PMC6262218</ArticleId><ArticleId IdType="pubmed">30496365</ArticleId></ArticleIdList></Reference><Reference><Citation>: Lessons learned from CHMP2B, implications for frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiology of Disease .2021;147: 10.1016/j.nbd.2020.105144 10.1016/j.nbd.2020.105144</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105144</ArticleId><ArticleId IdType="pubmed">33144171</ArticleId></ArticleIdList></Reference><Reference><Citation>: Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genetics .2005;37(8) : 10.1038/ng1609 806-808 10.1038/ng1609</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1609</ArticleId><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>